Lopinavir/Ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 Primeva phase 2/3 randomized trial. Tubiana, R.; Mandelbrot, L.; Le Chenadec, J.; Delmas, S.; Rouzioux, C.; Hirt, D.; Treluyer, J.M.; Ekoukou, D.; Bui, E.; Chaix, M.L.; Blanche, S.; Warszawski, J.. Clin Inf Dis. 2013; 57: p.891–902. doi:10.1093/cid/cit390Article
Épidémiologie clinique